
Viking Therapeutics Inc. (NASDAQ: VKTX) stock is soaring after the company delivered its third-quarter earnings report. The clinical-stage biopharmaceutical company is not profitable and is not generating revenue. However, investors cheered the company’s news that Phase 3 trials for its injectable weight loss treatment, VK2735, are proceeding as scheduled.
It’s impossible to ignore the importance of the company’s dual GLP-1/GIP receptor agonist. The company has other drugs in its pipeline. For example, its VK2809 candidate is in Phase 2 trials to treat non-alcoholic steatohepatitis (NASH). It also has an oral drug, VK0214, which targets a rare genetic neurological disorder.